Video
Obesity Paradox in prostate cancer: potential explanations and next research steps
Author(s):
Video Player is loading.
Vinayak G. Wagaskar, MBBS, shares potential explanations for the “obesity paradox”—improved survival outcomes in patients with a high body mass index (BMI)—in patients with metastatic castration-resistant prostate cancer (mCRPC). A study presented at the 2021 European Association of Urology showed improved survival outcomes in obese patients with mCRPC compared with overweight and normal weight patients. In the video also discusses next steps with this research.
Wagaskar is an instructor of urology at Mount Sinai in New York City
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
Laura Davis, MD, on persistent poverty and early onset prostate cancer
Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
Post-RP incontinence: Low procedure rates examined
Data link incontinence severity to post-radical prostatectomy care
Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
Expert discusses differentiating prostate cancer from age-related issues
Related Content
